As of April 2026, CJC-1295 and Ipamorelin have been removed from the Food and Drug Administrations (FDA) Category 2 restricted list, with formal review of compounding eligibility scheduled for July 2026
IGF-1 LR3 Product Description Product Overview IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arginine 3) is a synthetic, recombinant analog of the naturally occurring IGF-1 protein, engineered for enhanced stability and potency in laboratory and research applications
However, the actual increase in the proportion of fatty acid oxidation is limited by multiple factors
The most common side effects are gastrointestinal: nausea, diarrhea, decreased appetite, vomiting, constipation, and abdominal pain
The GIP pathway regulates glucose-dependent insulin secretion and may influence fat storage and energy balance through distinct brain regions